Crispr gene therapy of fusion gene related cancers

2-30. (canceled)

A method for treating or ameliorating a subject suffering from a fusion gene related cancer, the method comprising administrating to the subject a composition comprising:

• a first gRNA bound to an RNA-guided endonuclease forming a first ribonucleoprotein complex, wherein said first gRNA comprises a first targeting sequence complementary to a first target sequence in an intron in the 5′ region of a fusion gene;
• and
• a second gRNA bound to an RNA-guided endonuclease forming a second ribonucleoprotein complex, wherein said second gRNA comprises a second targeting sequence complementary to a second target sequence in an intron in the 3′ region of the fusion gene.

An in vitro method for deleting part of a fusion gene in a cell, the method comprising contacting the cell with a composition comprising:

• a first gRNA bound to an RNA-guided endonuclease forming a first ribonucleoprotein complex, wherein said first gRNA comprises a first targeting sequence complementary to a first target sequence in an intron in the 5′ region of a fusion gene;
• and
• a second gRNA bound to an RNA-guided endonuclease forming a second ribonucleoprotein complex, wherein said second gRNA comprises a second targeting sequence complementary to a second target sequence in an intron in the 3′ region of the fusion gene.